In Shanghai's Pudong New Area, Shanghai GoBroad Cancer Hospital, affiliated to China Pharmaceutical University, is set to undertake 30 new drug clinical research projects by the end of this year, focusing on challenging and severe diseases.

This research-oriented hospital, located in Waigaoqiao, aims to bridge the gap between clinical needs and pharmaceutical innovation, speeding up the process of turning scientific discoveries into better care for patients.

Shanghai GoBroad Cancer Hospital is committed to promoting clinical transformation and clinical research services. [Photo/WeChat ID: pdnews]

Despite its modest size, the hospital has already launched over 20 clinical studies on new drugs and is in negotiations for an additional 18 projects. Leveraging AI-driven systems, it has significantly shortened the time required for clinical trial design, enhancing efficiency.

The hospital collaborates with both startups and multinational pharmaceutical companies, such as Roche, which recently gained approval for a new indication of its innovative bispecific antibody, Glofitamab, in China. Additionally, local biotech firms like Sunshine Guojian and Mabwell Bioscience are making strides in ulcerative colitis treatment and ADC therapies, respectively.

Pudong's thriving biomedical industry, coupled with its vast medical resources, provides a fertile ground for such advancements. The district's commitment to integrating medical, academic, and industrial resources is fostering an ecosystem where innovative medicines can swiftly reach patients, positioning Pudong as a global leader in biomedical innovation.